Coagulation Abnormalities in the Critically Ill

  • Marcel Levi
  • Steven M. Opal


Bleeding is one of the major complications of surgery. Serious intraoperative and postoperative bleeding may be caused not only by a local problem in surgical hemostasis, such as a failed ligature, but can also be caused by a defect in the hemostatic system. Surgical hemostasis and an adequate function of the coagulation system are complementary; in some cases, a patient with a (minor) hemostatic defect may be operated upon without any specific perioperative intervention in the coagulation system, whereas in other instances improvement of blood coagulation may be necessary before surgery.1


Coagulation Factor Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation Thrombotic Thrombocytopenic Purpura Coagulation Abnormality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Levi M, van der Poll T. Hemostasis and coagulation. In: Norton JA, Bollinger RA, Chang AE, Lowry SF, editors. Surgery: scientific basis and current practice. 2001.Google Scholar
  2. 2.
    Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222–231.PubMedCrossRefGoogle Scholar
  3. 3.
    Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol. 1996;93:460–463.PubMedCrossRefGoogle Scholar
  4. 4.
    MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55:39–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Stephan F, Hollande J, Richard O, et al. Thrombocytopenia in a surgical ICU. Chest. 1999;115:1363–1370.PubMedCrossRefGoogle Scholar
  6. 6.
    Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother. 1997;31:285–289.PubMedGoogle Scholar
  7. 7.
    Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL. The time course of platelet counts in critically ill patients. Crit Care Med. 2002;30:753–756.PubMedCrossRefGoogle Scholar
  8. 8.
    Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871–1876.PubMedCrossRefGoogle Scholar
  9. 9.
    Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest. 1993;104:1243–1247.PubMedCrossRefGoogle Scholar
  10. 10.
    Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002;30:1765–1771.PubMedCrossRefGoogle Scholar
  11. 11.
    Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med. 1999;25:63–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. d-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest. 2002;121:1262–1268.PubMedCrossRefGoogle Scholar
  13. 13.
    Owings JT, Gosselin RC, Anderson JT, Battistella FD, Bagley M, Larkin EC. Practical utility of the d-dimer assay for excluding thromboembolism in severely injured trauma patients. J Trauma. 2001;51:425–429.PubMedCrossRefGoogle Scholar
  14. 14.
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.PubMedCrossRefGoogle Scholar
  15. 15.
    Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost. 1998;79:1111–1115.PubMedGoogle Scholar
  16. 16.
    Greaves M, Preston FE. Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: Lippingcott William&Wilkins; 2001. p. 1031–1043.Google Scholar
  17. 17.
    Edmunds LH. Hemostatic problems in surgical patients. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis. Basic principles and clinical practice. Philadelphia: Lippingcott William&Wilkins; 2001. p. 1031–1043.Google Scholar
  18. 18.
    Kitchen S, Preston FE. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost. 1999;25:17–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med. 2003;31:299–305.PubMedCrossRefGoogle Scholar
  20. 20.
    Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med. 2000;28:451–457.PubMedCrossRefGoogle Scholar
  21. 21.
    Folman CC, Linthorst GE, van Mourik J, et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost. 2000;83:923–930.PubMedGoogle Scholar
  22. 22.
    Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114–120.PubMedCrossRefGoogle Scholar
  23. 23.
    Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program). 2003;497–519.Google Scholar
  24. 24.
    Levi M, ten Cate H. Disseminated intravascular coagulation [Review] [52 refs]. N Engl J Med. 1999;341:586–592.PubMedCrossRefGoogle Scholar
  25. 25.
    Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003;23:745–753.PubMedCrossRefGoogle Scholar
  26. 26.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335.PubMedCrossRefGoogle Scholar
  27. 27.
    Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535–555.PubMedCrossRefGoogle Scholar
  28. 28.
    Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27–30.PubMedGoogle Scholar
  29. 29.
    Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.PubMedCrossRefGoogle Scholar
  30. 30.
    Tsai HM. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2003;23:388–396.PubMedCrossRefGoogle Scholar
  31. 31.
    Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart. 2001;86:18e.CrossRefGoogle Scholar
  32. 32.
    Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207–214.PubMedCrossRefGoogle Scholar
  33. 33.
    Levi M, de Jonge E, Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev. 2002;16:217–223.PubMedCrossRefGoogle Scholar
  34. 34.
    Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004;124:567–576.PubMedCrossRefGoogle Scholar
  35. 35.
    Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.PubMedGoogle Scholar
  36. 36.
    Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924–1933.PubMedCrossRefGoogle Scholar
  37. 37.
    Stefanidis I, Hagel J, Frank D, Maurin N. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clin Nephrol. 1996;46:199–205.PubMedGoogle Scholar
  38. 38.
    Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999;23:979–983.PubMedCrossRefGoogle Scholar
  39. 39.
    Rodgers RP, Levin J. A critical reappraisal of the bleeding time [Review] [231 refs]. Semin Thromb Hemost. 1990;16:1–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Forestier F, Coiffic A, Mouton C, Ekouevi D, Chene G, Janvier G. Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth. 2002;89:715–721.PubMedCrossRefGoogle Scholar
  41. 41.
    Levi M. Cancer and DIC. Haemostasis. 2001;31(Suppl 1):47–48.PubMedGoogle Scholar
  42. 42.
    Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost. 1992;68:250–252.PubMedGoogle Scholar
  43. 43.
    Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361–369.PubMedCrossRefGoogle Scholar
  44. 44.
    Hellstern P, Muntean W, Schramm W, Seifried E, Solheim B. Practical guidelines for the clinical use of plasma. Thromb Res. 2002;107(Suppl 1):S53.PubMedCrossRefGoogle Scholar
  45. 45.
    Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301–2311.PubMedCrossRefGoogle Scholar
  46. 46.
    Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years [Review] [66 refs]. Blood. 1997;90:2515–2521.PubMedGoogle Scholar
  47. 47.
    Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints [see comments]. Lancet. 1999;354:1940–1947.PubMedCrossRefGoogle Scholar
  48. 48.
    Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet. 2000;355(9212):1303–1309.PubMedCrossRefGoogle Scholar
  49. 49.
    Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201–205.PubMedCrossRefGoogle Scholar
  50. 50.
    Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002;42:114–124.PubMedCrossRefGoogle Scholar
  51. 51.
    Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol. 2001;38:48–50.PubMedCrossRefGoogle Scholar
  52. 52.
    Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176(5):483–490.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Marcel Levi
    • 1
  • Steven M. Opal
    • 2
  1. 1.Department of MedicineAcademic Medical CenterAmsterdamThe Netherlands
  2. 2.Division of Infectious Diseases, The Memorial Hospital of Rhode IslandBrown UniversityPawtucketUSA

Personalised recommendations